Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NAT1 | P18440 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757078 | 1.00 | CISD1 (0.63) | CISD1MAOBMAOATDP1MEN1 | |
| SCHEMBL24217825 | 0.85 | CISD1 (0.71) | CISD1MAOBMAOAMEN1KMT2A | |
| SCHEMBL24217823 | 0.84 | CISD1 (0.70) | CISD1MAOBMAOAMEN1KMT2A | |
| SCHEMBL12008799 | 0.82 | MAPT (0.76) | CISD1MAOATDP1MEN1KMT2A | |
| SCHEMBL12008558 | 0.81 | CACNA1B (0.73) | CISD1MAOATDP1MEN1KMT2A | |
| SCHEMBL17397858 | 0.80 | CISD1 (0.73) | CISD1MAOBMAOAMEN1KMT2A | |
| SCHEMBL17397856 | 0.80 | CISD1 (0.73) | CISD1MAOBMAOAMEN1KMT2A | |
| SCHEMBL17397857 | 0.80 | CISD1 (0.73) | CISD1MAOBMAOAMEN1KMT2A | |
| SCHEMBL1125306 | 0.79 | CISD1 (0.75) | CISD1MAOBMAOAMEN1KMT2A | |
| SCHEMBL1125307 | 0.79 | CISD1 (0.75) | CISD1MAOBMAOAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305121-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | BURHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-12-02 | — | — | US | disclosed |
| US-20070203236-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | UNITED STATES GOVERNMENT | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203236-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | FADS2, ACOT7, FADS1 | CISD1 624/4885MAOB 1269/4885MAOA 1256/4885 |
| US-20100305121-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | FADS2, ACOT7, FADS1 | CISD1 624/4885MAOB 1269/4885MAOA 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.